Development of a Risk Prediction Score for Occult Cancer in Patients With VTE.
Détails
ID Serval
serval:BIB_D3231B01AB1B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Development of a Risk Prediction Score for Occult Cancer in Patients With VTE.
Périodique
Chest
Collaborateur⸱rice⸱s
RIETE Investigators
Contributeur⸱rice⸱s
Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Bertoletti L., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Papadakis M., Aibar M.A., Alfonso M., Asensio-Cruz M.I., Auguet T., Arcelus J.I., Barba R., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañas I., Ceausu A., Chic N., Culla A., Del Pozo R., Del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Duffort M., Elias-Hernández T., Falgá C., Fernández-Aracil C., Fernández-Capitán C., Fidalgo M.A., Font C., Font L., Gallego P., García M.A., García-Bragado F., García-Rodenas M., Gómez V., González J., Grau E., Grimón A., Guijarro R., Guirado L., Gutiérrez J., Hernández-Comes G., Hernández-Blasco L., Hernando-López E., Jara-Palomares L., Jaras M.J., Jiménez D., Joya M.D., Llamas P., Lecumberri R., Lobo J.L., López-Jiménez L., López-Reyes R., López-Sáez J.B., Lorente M.A., Lorenzo A., Maestre A., Marchena P.J., Martín M., Martín-Martos F., Monreal M., Nieto J.A., Nieto S., Núñez A., Núñez M.J., Odriozola M., Otalora S., Otero R., Ovejero A., Pedrajas J.M., Pérez G., Pérez-Ductor C., Peris M.L., Porras J.A., Reig O., Riera-Mestre A., Riesco D., Rivas A., Rodríguez-Dávila M.A., Rosa V., Ruiz-Artacho P., Ruiz-Giménez N., Sahuquillo J.C., Sala-Sainz M.C., Sampériz A., Sánchez R., Sanz O., Soler S., Sopeña B., Suriñach J.M., Tolosa C., Trujillo-Santos J., Uresandi F., Valero B., Valle R., Vela J., Vicente P., Vidal G., Villalobos A., Villalta J., Vanassche T., Verhamme P., Wells P., Hirmerova J., Malý R., Salgado E., Bertoletti L., Bura-Riviere A., Farge-Bancel D., Hij A., Mahé I., Merah A., Moustafa F., Papadakis M., Braester A., Brenner B., Tzoran I., Antonucci G., Barillari G., Bertone A., Bilora F., Bortoluzzi C., Ciammaichella M., Di Girolamo C., Di Micco P., Duce R., Ferrazzi P., Giorgi-Pierfranceschi M., Grandone E., Lodigiani C., Maida R., Mastroiacovo D., Pace F., Pesavento R., Pinelli M., Poggio R., Prandoni P., Rota L., Tiraferri E., Tonello D., Tufano A., Visonà A., Zalunardo B., Drucka E., Kigitovica D., Skride A., Sousa M.S., Bosevski M., Zdraveska M., Bounameaux H., Mazzolai L.
ISSN
1931-3543 (Electronic)
ISSN-L
0012-3692
Statut éditorial
Publié
Date de publication
03/2017
Peer-reviewed
Oui
Volume
151
Numéro
3
Pages
564-571
Langue
anglais
Notes
Publication types: Journal Article ; Observational Study
Publication Status: ppublish
Publication Status: ppublish
Résumé
The benefits of a diagnostic workup for occult cancer in patients with VTE are controversial. Our aim was to provide and validate a risk score for occult cancer in patients with VTE.
We designed a nested case-control study in a cohort of patients with VTE included in the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry from 2001 to 2014. Cases included cancer detected beyond the first 30 days and up to 24 months after VTE. Control subjects were defined as patients with VTE with no cancer in the same period.
Of 5,863 eligible patients, 444 (7.6%; 95% CI, 6.8%-8.2%) were diagnosed with occult cancer. On multivariable analysis, variables selected were male sex, age > 70 years, chronic lung disease, anemia, elevated platelet count, prior VTE, and recent surgery. We built a risk score assigning points to each variable. Internal validity was confirmed using bootstrap analysis. The proportion of patients with cancer who scored ≤ 2 points was 5.8% (241 of 4,150) and that proportion in those who scored ≥ 3 points was 12% (203 of 1,713). We also identified scores divided by sex and age subgroups.
This is the first risk score that has identified patients with VTE who are at increased risk for occult cancer. Our score needs to be externally validated.
We designed a nested case-control study in a cohort of patients with VTE included in the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry from 2001 to 2014. Cases included cancer detected beyond the first 30 days and up to 24 months after VTE. Control subjects were defined as patients with VTE with no cancer in the same period.
Of 5,863 eligible patients, 444 (7.6%; 95% CI, 6.8%-8.2%) were diagnosed with occult cancer. On multivariable analysis, variables selected were male sex, age > 70 years, chronic lung disease, anemia, elevated platelet count, prior VTE, and recent surgery. We built a risk score assigning points to each variable. Internal validity was confirmed using bootstrap analysis. The proportion of patients with cancer who scored ≤ 2 points was 5.8% (241 of 4,150) and that proportion in those who scored ≥ 3 points was 12% (203 of 1,713). We also identified scores divided by sex and age subgroups.
This is the first risk score that has identified patients with VTE who are at increased risk for occult cancer. Our score needs to be externally validated.
Mots-clé
Age Factors, Aged, Aged, 80 and over, Anemia/epidemiology, Case-Control Studies, Female, Humans, Lung Diseases/epidemiology, Male, Middle Aged, Multivariate Analysis, Neoplasms/diagnosis, Neoplasms/epidemiology, Pulmonary Embolism/epidemiology, Registries, Reproducibility of Results, Risk Assessment, Sex Factors, Spain/epidemiology, Surgical Procedures, Operative/statistics & numerical data, Thrombocytosis/epidemiology, Venous Thromboembolism/epidemiology, Venous Thrombosis/epidemiology, neoplasm, pulmonary embolism, risk, screening, venous thromboembolism
Pubmed
Web of science
Création de la notice
12/10/2018 12:54
Dernière modification de la notice
20/08/2019 15:53
Données d'usage
